Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Shield Therapeutics Plc | STX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.05 | 1.75% | 2.90 | 16:35:01 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.85 | 2.85 | 2.85 | 2.90 | 2.85 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 22/11/2024 17:52 by qipincha WatchlistSTX Shield Therapeutics STX Last Price £0.03 Fair Value Select Price target increased by 88% to UK£0.30 Up from UK£0.16, the current price target is an average from 2 analysts. New target price is 917% above last closing price of UK£0.029. Stock is down 51% over the past year. The company is forecast to post a net loss per share of US$0.014 next year compared to a net loss per share of US$0.046 last year. —- From Simply Wall St |
Posted at 12/11/2024 14:45 by purchaseatthetop Interesting comparisons between STX and CREO. So thanks to Parob for coming to the board to try to upset me.CREO have spent £157m if retained losses getting to losing £10m every six months. Overhead of £40m a year. Sales about £30m. No revenue growth. 47% gross margin. STX have spent about the same of retained losses getting to losing the same amount every six months. Overhead about the same. 250% revenue growth with similar revenue now. same gross margin. Likely £65m plus revenue 2025. STX market cap £21k CREO market cap £75m Certainly seems one is under or overvalued. Very similar in many ways. |
Posted at 09/11/2024 11:09 by weatherman The mandatory offer was due to UK regulation, AOP did not wish to win then. So, I'm not sure AOP are trying to take over STX through sharp practices - they don't want STX to be a drain on their own profits until STX is in the black. They have an option to buy $10m at 4p to support the price, which may give them over 50%, but they can offer some of that back to existing shareholders. By supporting STX they can see a very profitable stake for AOP. |
Posted at 09/11/2024 10:25 by purchaseatthetop 28/9/23 RNSThe aggregate net proceeds from the Equity Fundraising, together with the SWK Financing, will be used by Shield to further invest in US commercial activities with the goal to accelerate the launch curve and increase the net sales price for Accrufer®, provide additional working capital for the build-up of inventories and receivables, and allow the Company to repay the outstanding balance of US$5.7m on the Existing AOP Loan. 3/10/23 RNS London, UK - 3 October 2023: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company, is pleased to announce that further to the announcement on 28 September 2023 setting out details of a $20 million senior secured debt facility from SWK Funding LLC and an Equity Financing (the "Financing Announcement"), the SWK Financing has now been completed. The Placing, the Subscription and the REX Retail Offer remain conditional upon the Placing Agreement becoming unconditional and not having been terminated in accordance with its terms. The Placing Agreement remains conditional, amongst other things, upon the following: · the Company having complied with its obligations and having satisfied all conditions under the Placing Agreement, which fall to be performed on or satisfied prior to Admission; The AOP loan of $5.7m was repaid and did not appear on the balance sheet at 31/12/23. The only debt is the SWK loan except the Sallyport invoice financing now and we await to see the treatment of the new China $5.6m milestone payment from 2024. But rest assured, only SWK have security. Not AOP. The pwhite idea is that if the China $13.4m milestone advance has not arrived at end of 2026 then STX will fall into default. By end of 2026 STX will be churning out cash and dealing with any potential problem will not be an issue. Everything is being done to get them to cash breakeven. End of 2025. |
Posted at 09/11/2024 10:02 by pwhite73 zeus19 - "How does that work? The covenants are with SWK."I don't think you quite understand that financial arrangement and what has proceeded since. 1. The SWK covenants over STX assets is conditional on STX repaying the AOP loan and AOP releasing its ownership over the IP and other assets including Accrufer. 2. The SWK debt facility was entered into on 28/09/2023 it matures on 28/09/2028. Its important to remember its only an available debt facility that the company can draw on should it need to. I am not aware it has drawn on the debt facility as yet. 3. AOP have effectively said NO to the debt facility. What they have said to STX is - "as we are your largest shareholder if you need any money to progress Accrufer and other projects you will borrow it from us not SWK". 4. Hence RNS 03/07/2024 - "Shield Enters into $5.7 million Milestone Monetization Agreement with AOP" 5. Hence RNS 29/10/2024 - "and the entering into of a non-binding term sheet with AOP Health International Management AG ("AOP Health") for the potential provision of $10 million of new equity." 5. Now this is also extremely important. RNS 03/07/2024 - "Further, if the Approval Milestone has not been triggered by 31 December 2026, or in the event the Agreement is terminated, including at Shield's election or due to a breach by Shield of its terms, the Advance plus accrued interest and fees at the interest rate of SOFR+9.25% (calculated from the date of the Advance until the day of payment) and an exit fee of 6.5% of the Advance will be payable by Shield to AOP. The Advance will be secured inter alia by AOP's right to receive the ASK Approval Milestone." Please accept my apologies for the long winded post but its important retail shareholders understand why the share price is so low and in AOP's interest for STX to default which leaves them owning STX and all its assets. |
Posted at 09/11/2024 08:17 by zeus19 How does that work? The covenants are with SWK. It's in AOP's interest to keep STX alive or they walk away with nothing, just like the other shareholders if STX default |
Posted at 30/10/2024 18:04 by qipincha Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some ScrutinyThe Shield Therapeutics plc (LON:STX) share price has softened a substantial 28% over the previous 30 days, handing back much of the gains the stock has made lately. The drop over the last 30 days has capped off a tough year for shareholders, with the share price down 45% in that time. Since its price has dipped substantially, Shield Therapeutics may be sending very bullish signals at the moment with its price-to-sales (or "P/S") ratio of 1.6x, since almost half of all companies in the Pharmaceuticals industry in the United Kingdom have P/S ratios greater than 4.7x and even P/S higher than 8x are not unusual. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so limited. How Has Shield Therapeutics Performed Recently? Shield Therapeutics certainly has been doing a good job lately as it's been growing revenue more than most other companies. It might be that many expect the strong revenue performance to degrade substantially, which has repressed the share price, and thus the P/S ratio. If not, then existing shareholders have reason to be quite optimistic about the future direction of the share price. Is There Any Revenue Growth Forecasted For Shield Therapeutics? Shield Therapeutics' P/S ratio would be typical for a company that's expected to deliver very poor growth or even falling revenue, and importantly, perform much worse than the industry. Retrospectively, the last year delivered an exceptional 224% gain to the company's top line. The latest three year period has also seen an incredible overall rise in revenue, aided by its incredible short-term performance. So we can start by confirming that the company has done a tremendous job of growing revenue over that time. Shifting to the future, estimates from the three analysts covering the company suggest revenue should grow by 171% over the next year. Meanwhile, the rest of the industry is forecast to only expand by 8.6%, which is noticeably less attractive. With this in consideration, we find it intriguing that Shield Therapeutics' P/S sits behind most of its industry peers. Apparently some shareholders are doubtful of the forecasts and have been accepting significantly lower selling prices. hxxps://simplywall.s |
Posted at 29/10/2024 13:42 by purchaseatthetop Jaknife. I never said they were fully funded. I said they would need an extra $5m from Sallyport (and that was announced today).“purchaseatthe Just to repeat. I used to hold STX and exited on the way down when it became clear that things were going to get a lot worse before they got better. I carried on watching and waiting. The recent accounts showing great prescription growth combined with growing revenue per unit was key. It rapidly moves STX to EBITDA positive. The new CFO has reorganised the finances so in my view no new raise is needed. The Sallyport invoice financing is key. The limit is $10m now but that can be raised any time to say $15m to release more cash” No company can go down to zero cash do raising from AOP makes sense. The prescriptions were within the ranges I thought would arrive but the Rx was slightly lower. “purchaseatthe Homebrewrus. Interesting read. Good analysis over the minimum revenues. I think the $175 per item for Q3 24 is too low. More like $185. I also think that prescription growth will be higher. Somewhere between the 43k and the Hardman 47k odd. Not sure that the $5.7m can be considered revenue as it is also a creditor!” |
Posted at 11/10/2024 19:44 by hms_trader For the sudden influx of bitter (ex)ENET holders/those that have a gripe with PATT; the numbers speak for themselves here at STX. It's all in the open. There are many here that know the business, the issues, and the prospects well having been here a long time through the ups and downs and are thus not at risk of being misled into buying or into selling by ad hominem. STX is an excellent recovery play for multiple reasons so, do us all a huge favour, stop clogging up this board with all your garbage and do one back to either the ENET board or elsewhere. Alternatively buy some STX shares, and take a seat at the back quietly unless you have something worthwhile to add. You may just make your ENET losses back and some. |
Posted at 24/7/2024 17:48 by r9505571 Shield Therapeutics (LON:STX) is currently experiencing a challenging period. Its stock price has been highly volatile, recently trading at around 1.60 GBX, representing a significant decline over the past year [oai_citation:1,Shie |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
